Exosomes as Efficient Nanocarriers in Osteosarcoma: Biological Functions and Potential Clinical Applications.
biomarker
exosomes
osteosarcoma
targeted delivery
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
07
2021
accepted:
23
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Osteosarcoma is the most common bone tumor affecting both adolescents and children. Although localized osteosarcoma has an overall survival of >70% in the clinic, metastatic, refractory, and recurrent osteosarcoma have poorer survival rates. Exosomes are extracellular vesicles released by cells and originally thought to be a way for cells to discard unwanted products. Currently, exosomes have been reported to be involved in intercellular cross-talk and induce changes in cellular behavior by transferring cargoes (proteins, DNA, RNA, and lipids) between cells. Exosomes regulate osteosarcoma progression, and processes such as tumorigenesis, proliferation, metastasis, angiogenesis, immune evasion, and drug resistance. Increasing evidences shows that exosomes have significant potential in promoting osteosarcoma progression and development. In this review, we describe the current research status of exosomes in osteosarcoma, focusing on the biological functions of osteosarcoma exosomes as well as their application in osteosarcoma as diagnostic biomarkers and therapeutic targets.
Identifiants
pubmed: 34712664
doi: 10.3389/fcell.2021.737314
pmc: PMC8546119
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
737314Informations de copyright
Copyright © 2021 Yang, Huang, Guo, Wang, Yang, Wu, Jing and Shao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
ACS Nano. 2018 Aug 28;12(8):7482-7496
pubmed: 30071163
Nat Rev Nephrol. 2017 Dec;13(12):731-749
pubmed: 29081510
Theranostics. 2018 Jan 1;8(1):237-255
pubmed: 29290805
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Sarcoma. 2012;2012:704872
pubmed: 22550423
J Vis Exp. 2018 May 6;(135):
pubmed: 29782011
Adv Exp Med Biol. 2020;1258:189-197
pubmed: 32767243
Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6239-6244
pubmed: 30338784
J Cell Physiol. 2020 May;235(5):4734-4745
pubmed: 31637737
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
Arch Med Res. 2021 Feb;52(2):200-210
pubmed: 33162186
Aging (Albany NY). 2020 Dec 13;12(23):23598-23608
pubmed: 33310972
Immunol Lett. 2006 Nov 15;107(2):102-8
pubmed: 17067686
Oncotarget. 2016 Jul 12;7(28):43570-43587
pubmed: 27259278
Front Oncol. 2021 Feb 08;10:606906
pubmed: 33628730
J Nanobiotechnology. 2020 Oct 22;18(1):151
pubmed: 33092576
J Extracell Vesicles. 2014 Aug 04;3:
pubmed: 25143819
Cancer Lett. 2020 Oct 10;490:54-65
pubmed: 32682951
Nanoscale. 2018 Aug 2;10(30):14554-14562
pubmed: 30024587
J Transl Med. 2005 Mar 02;3(1):10
pubmed: 15740633
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
Pathol Res Pract. 2019 Dec;215(12):152688
pubmed: 31727503
Transl Oncol. 2018 Oct;11(5):1137-1146
pubmed: 30053712
Cancers (Basel). 2019 Dec 03;11(12):
pubmed: 31816885
Curr Opin Pharmacol. 2014 Jun;16:15-23
pubmed: 24632219
Acta Med Okayama. 2018 Apr;72(2):165-174
pubmed: 29674765
Front Oncol. 2013 Sep 17;3:230
pubmed: 24062983
Am J Transl Res. 2021 Mar 15;13(3):882-897
pubmed: 33841628
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Adv Biosyst. 2020 Sep;4(9):e2000152
pubmed: 32803878
J Bone Oncol. 2020 Feb 04;21:100280
pubmed: 32082984
J Immunol. 2000 Aug 1;165(3):1259-65
pubmed: 10903724
Int J Oncol. 2016 Jul;49(1):189-96
pubmed: 27176642
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Mol Ther Nucleic Acids. 2020 Sep 4;21:900-915
pubmed: 32810692
Front Oncol. 2018 Jan 26;8:4
pubmed: 29435436
Cancer Med. 2020 Sep;9(17):6354-6366
pubmed: 32673448
PLoS One. 2015 Aug 28;10(8):e0133592
pubmed: 26317203
Clin Chim Acta. 2018 Dec;487:363-368
pubmed: 29045858
Int J Mol Sci. 2019 Sep 27;20(19):
pubmed: 31569680
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
PLoS One. 2016 Nov 3;11(11):e0166027
pubmed: 27812189
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
J Biol Chem. 2014 Feb 14;289(7):3869-75
pubmed: 24398677
Expert Rev Proteomics. 2009 Jun;6(3):267-83
pubmed: 19489699
Cell Biol Int. 2021 Apr;45(4):858-868
pubmed: 33325136
J Investig Med. 2020 Apr;68(4):893-901
pubmed: 32060049
Front Cell Dev Biol. 2020 May 25;8:353
pubmed: 32523950
Am J Orthop (Belle Mead NJ). 2015 Dec;44(12):547-53
pubmed: 26665241
Ann Surg Oncol. 2018 Dec;25(Suppl 3):936-937
pubmed: 30456679
Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18
pubmed: 21317869
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Mol Med (Berl). 2013 Apr;91(4):431-7
pubmed: 23519402
Signal Transduct Target Ther. 2021 Feb 11;6(1):59
pubmed: 33568623
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751693
Mol Cancer. 2019 Jul 5;18(1):116
pubmed: 31277663
Biochim Biophys Acta. 2012 Jul;1820(7):940-8
pubmed: 22503788
Cancer Lett. 2015 Oct 10;367(1):26-33
pubmed: 26189430
J Cell Physiol. 2018 Aug;233(8):6158-6172
pubmed: 29323709
Biochem Biophys Res Commun. 2018 Jun 2;500(2):170-176
pubmed: 29626470
Int J Biol Sci. 2018 Feb 12;14(3):321-330
pubmed: 29559849
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Hum Cell. 2019 Jan;32(1):64-74
pubmed: 30506278
Oncol Res. 2019 Sep 23;27(9):979-986
pubmed: 30180920
Theranostics. 2020 Jan 1;10(1):411-425
pubmed: 31903129
Nature. 2009 Mar 26;458(7237):445-52
pubmed: 19325624
In Vitro Cell Dev Biol Anim. 2018 Jun;54(6):423-429
pubmed: 29748909
Cell Physiol Biochem. 2017;42(6):2242-2254
pubmed: 28817816
Angew Chem Int Ed Engl. 2018 Aug 27;57(35):11198-11202
pubmed: 29905979
Nature. 2007 Nov 15;450(7168):435-9
pubmed: 17960135
Oncotarget. 2017 Jun 6;8(44):75968-75978
pubmed: 29100284
Aging (Albany NY). 2019 Nov 7;11(21):9581-9596
pubmed: 31699956
Exp Cell Res. 2017 Sep 15;358(2):369-376
pubmed: 28712929
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Curr Opin Cell Biol. 2015 Aug;35:69-77
pubmed: 26001269
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Crit Rev Oncol Hematol. 2009 Mar;69(3):187-98
pubmed: 18675551
Gene. 2019 Aug 20;710:246-257
pubmed: 31176732
Cancer Cell Int. 2021 Apr 1;21(1):192
pubmed: 33794884
Mol Cancer. 2019 Mar 30;18(1):52
pubmed: 30925917
Mol Ther. 2008 Apr;16(4):782-90
pubmed: 18362931
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
J Cell Physiol. 2021 May;236(5):3354-3365
pubmed: 33044018
Int J Biol Sci. 2018 Sep 1;14(11):1513-1520
pubmed: 30263004
Cell Stem Cell. 2009 Mar 6;4(3):206-16
pubmed: 19265660
Int J Nanomedicine. 2019 Nov 01;14:8603-8610
pubmed: 31802872
Transl Oncol. 2014 Jun 17;7(3):331-40
pubmed: 25180057
Microbiol Mol Biol Rev. 2016 Mar 02;80(2):369-86
pubmed: 26935137
Theranostics. 2021 Jan 1;11(3):1473-1492
pubmed: 33391546
Biomed Res Int. 2021 Mar 25;2021:7358153
pubmed: 33834074
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Front Immunol. 2018 Apr 30;9:738
pubmed: 29760691
Oncologist. 2004;9(4):422-41
pubmed: 15266096
Oncoimmunology. 2020 Apr 12;9(1):1747677
pubmed: 32313728
Onco Targets Ther. 2020 Nov 23;13:12055-12066
pubmed: 33262606
Biochem Biophys Res Commun. 2014 Mar 7;445(2):381-7
pubmed: 24525123
Clin Cancer Res. 2017 Jul 15;23(14):3721-3733
pubmed: 28053020
Int J Mol Sci. 2019 Oct 22;20(20):
pubmed: 31652569
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
pubmed: 17237035
Tumour Biol. 2017 Jul;39(7):1010428317709991
pubmed: 28695772
Mol Cancer. 2019 Mar 15;18(1):41
pubmed: 30876419
J Cell Mol Med. 2020 Feb;24(3):2202-2214
pubmed: 31923350